Overview
Sponsor-declared trial summary
Immune system diseases
Pivotal Maintenance Sub-Study Cohort 1: To assess the efficacy of duvakitug as maintenance therapy compared with placebo in participants with moderately to severely active CD
Key facts
- Sponsor
- Sanofi-Aventis Recherche & Developpement
- Participant type
- Pediatric, Patients
- Age range
- 0-17 years, 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Immune System Diseases [C20]
- Decision date (initial)
- 2026-03-01
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
- Funding sources
- Sanofi-Aventis Recherche & Developpement
External identifiers
- EU CT number
- 2025-521037-86-00
- WHO UTN
- U1111-1314-5471
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Efficacy, Safety, Pharmacokinetic
Pivotal Maintenance Sub-Study Cohort 1: To assess the efficacy of duvakitug as maintenance therapy compared with placebo in participants with moderately to severely active CD
Secondary objectives 4
- Pivotal Maintenance Sub-Study Cohort 1: To assess the efficacy of duvakitug as maintenance therapy by multiple measures of disease activity in participants with moderately to severely active CD
- Pivotal Maintenance Sub-Study Cohort 1: To evaluate the PK and immunogenicity of duvakitug in participants with moderately to severely active CD
- Pivotal Maintenance Sub-Study Cohort 1: To assess the safety of duvakitug as maintenance therapy compared with placebo in participants with moderately to severely active CD
- Open-Label Extension Sub-Study: To assess the safety of long-term administration of duvakitug in participants with moderately to severely active CD
Conditions and MedDRA coding
Immune system diseases
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 28.0 | PT | 10011401 | Crohn´s disease | 100000004856 |
Regulatory references
- Scientific advice from competent authorities
- European Medicines Agency
- EMA paediatric investigation plan (PIP)
- EMEA-000000-PIP00-00
- Plan to share IPD
- Yes
- IPD plan description
- Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 3
- Participants aged ≥18 and ≤80 years of age at Baseline. (Where locally permissible, participants 16 to <18 years of age who meet the definition of Tanner stage 5 for development)
- Pivotal Maintenance Sub-Study: Participants who achieved clinical response and completed endoscopy at the end of STARSCAPE-1
- OLE Sub-Study: Participants who complete the Pivotal Maintenance Sub-Study or participation in the TV48574-IMM-20038 Study
Exclusion criteria 2
- Participants with medical or compliance conditions that are deemed unsuitable for the study by the investigator
- Participants with a known hypersensitivity to duvakitug that makes the participant unsuitable for the study by the investigator
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 4
- Co-primary endpoints US/FDA: Pivotal Maintenance Sub-Study Cohort 1 • Proportion of participants achieving clinical remission (CDAI) at Week 40
- Co-primary endpoints US/FDA: Pivotal Maintenance Sub-Study Cohort 1 • Proportion of participants achieving Endoscopic Response (SES-CD) at Week 40
- Co-primary endpoints EU/EMA: Pivotal Maintenance Sub-Study Cohort 1 • Proportion of participants achieving clinical remission per PRO-2 at Week 40
- Co-primary endpoints EU/EMA: Pivotal Maintenance Sub-Study Cohort 1 • Proportion of participants achieving Endoscopic Response (SES-CD) at Week 40
Secondary endpoints 19
- Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving CDAI clinical response Week 40
- Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving SES-CD endoscopic remission at Week 40
- US/FDA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving CDAI clinical remission and endoscopic remission at Week 40
- EU/EMA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving PRO-2 clinical remission and endoscopic remission at Week 40
- US/FDA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving PRO-2 clinical remission at Week 40
- EU/EMA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving CDAI clinical remission at Week 40
- US/FDA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving corticosteroids free CDAI clinical remission at Week 40
- EU/EMA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving corticosteroids free PRO-2 remission at Week 40
- Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving ulcer-free endoscopy (in the subset of participants with ulcers at Baseline) at Week 40
- US/FDA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving clinical remission per CDAI at Week 40 in the subset of participants with clinical remission per CDAI at Week 0 (maintenance of clinical remission per CDAI)
- EU/EMA Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving clinical remission per PRO-2 at Week 40 in the subset of participants with clinical remission per PRO-2 at Week 0 (maintenance of clinical remission per PRO-2)
- Pivotal Maintenance Sub-Study Cohort 1: Change from Baseline in PROMIS-Fatigue Short Form 7a T-score at Week 40
- Pivotal Maintenance Sub-Study Cohort 1: Change from Baseline in IBDQ total score at Week 40
- Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants with no bowel urgency by NRS at Week 40
- Pivotal Maintenance Sub-Study Cohort 1: Incidence of CD related hospitalization by Week 40
- Pivotal Maintenance Sub-Study Cohort 1: Serum concentrations of duvakitug measured over time
- Pivotal Maintenance Sub-Study Cohort 1: Incidence of treatment- emergent antidrug antibody (ADA) against duvakitug
- Pivotal Maintenance Sub-Study Cohort 1: Incidence of treatment- emergent adverse events (TEAEs), treatment-emergent adverse events of special interest (TEAESIs), treatment-emergent serious adverse events (TESAEs) and TEAEs leading to permanent study intervention discontinuation
- Open-Label Extension Sub-Study: Incidence of TEAEs, TEAESIs, TESAEs, and TEAEs leading to permanent study intervention discontinuation
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 1
PRD12634307 · Product
- Active substance
- Duvakitug
- Substance synonyms
- Human IgG1 lambda monoclonal antibody against TL1A, TEV-48574, Human IgG1 lambda monoclonal antibody against TNFSF15
- Pharmaceutical form
- SOLUTION FOR INJECTION
- Route of administration
- SUBCUTANEOUS INJECTION
- Max daily dose
- 00 mg milligram(s)
- Max total dose
- 00 mg milligram(s)
- Max treatment duration
- 280 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- SANOFI AVENTIS RECHERCHE ET DEVELOPPEMENT (SAR)
- Paediatric formulation
- No
- Orphan designation
- No
Placebo 1
Matched placebo for test product
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Sanofi-Aventis Recherche & Developpement
- Sponsor organisation
- Sanofi-Aventis Recherche & Developpement
- Address
- 82 Avenue Raspail
- City
- Gentilly
- Postcode
- 94250
- Country
- France
Scientific contact point
- Organisation
- Sanofi-Aventis Recherche & Developpement
- Contact name
- Clinical Services and operations
Public contact point
- Organisation
- Sanofi-Aventis Recherche & Developpement
- Contact name
- Clinical Services and operations
Third parties 7
| Organisation | City, country | Duties |
|---|---|---|
| Fisher Clinical Services UK Limited ORG-100012049
|
Horsham, United Kingdom | Code 14 |
| MARKEN Germany GmbH ORG-100017196
|
Hamburg, Germany | Code 14 |
| ESMS Global Limited ORG-100023149
|
London, United Kingdom | Other |
| Psi CRO Greece ORG-100047165
|
Athens, Greece | Other |
| Teckro Limited ORG-100041454
|
Limerick, Ireland | Other |
| Psi Cro AG ORG-100034251
|
Zug, Switzerland | On site monitoring, Code 12, Other, Code 2, Code 5, Data management |
| Suvoda LLC ORG-100043523
|
Conshohocken, United States | Code 14, Interactive response technologies (IRT) |
Locations
15 EU/EEA countries · 146 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Authorised, recruitment pending | 9 | 9 |
| Belgium | Authorised, recruitment pending | 4 | 4 |
| Bulgaria | Authorised, recruitment pending | 11 | 9 |
| Czechia | Authorised, recruitment pending | 24 | 8 |
| France | Authorised, recruitment pending | 13 | 13 |
| Germany | Authorised, recruitment pending | 34 | 27 |
| Greece | Authorised, recruitment pending | 3 | 3 |
| Hungary | Authorised, recruitment pending | 8 | 5 |
| Italy | Authorised, recruitment pending | 14 | 13 |
| Lithuania | Authorised, recruitment pending | 2 | 2 |
| Netherlands | Authorised, recruitment pending | 2 | 3 |
| Norway | Authorised, recruitment pending | 2 | 2 |
| Poland | Authorised, recruitment pending | 60 | 38 |
| Slovakia | Authorised, recruitment pending | 10 | 4 |
| Spain | Authorised, recruitment pending | 8 | 6 |
| Rest of world
Serbia, Switzerland, South Africa, Georgia, United Arab Emirates, Chile, Brazil, United Kingdom, Kazakhstan, Taiwan, United States, Moldova, Republic of, China, Argentina, Ukraine, Japan, New Zealand, Australia, Turkey, Israel, Mexico, Canada, Korea, Republic of, Colombia, Saudi Arabia
|
— | 465 | — |
Investigational sites
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 230 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | d1-rdct-protocol-en-2025-521037-86 | 1 |
| Protocol (for publication) | d1-rdct-protocol-gr-GR-2025-521037-86 | 1 |
| Protocol (for publication) | d4-patient facing documents-cd-symptoms-diary-en-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient facing documents-cd-symptoms-diary-es-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient facing documents-cd-symptoms-diary-hu-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptomps-diary-it-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms diary-lt-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-at-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-bg-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-cz_2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-de-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-fr-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-fr-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-gr-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-nl-2025-521037-86 | 2 |
| Protocol (for publication) | d4-patient-facing-documents-cd-symptoms-diary-sk_2025-521037-86 | 2 |
| Protocol (for publication) | d4-rdct-patient-facing-documents-copyrighted-en-2025-521037-86 | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment and Informed Consent Procedure | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | NA |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | NA |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | NA |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_public | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Materials_Patient Advocacy Fact Sheet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Advocacy Fact Sheet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Advocacy Fact Sheet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Advocacy Fact Sheet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Advocacy Fact Sheet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Advocacy Fact Sheet_public | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Advocacy Fact Sheet | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Advocacy Fact Sheet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Advocacy Fact Sheet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Advocacy Fact Sheet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Advocacy Fact Sheet CD | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Advocacy Fact Sheet CD | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Advocacy Fact Sheet_BE-FR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Advocacy Fact Sheet_BE-NL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Leaflet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet CD | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Leaflet_BE-FR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Leaflet_BE-NL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Leaflet_public | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster CD | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Poster_BE-FR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Poster_BE-NL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Poster_public | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Physician Referral letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Physician referral letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Physician Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Physician Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Physician Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Physician Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Physician referral letter_CD_BE-FR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Physician referral letter_CD_BE-NL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Physician Referral Letter_public | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Translation Certificate | NA |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Patient Advocacy Fact Sheet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Advocacy Fact Sheet | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Advocacy Fact Sheet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Patient Leaflet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Leaflet | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Leaflet | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Leaflet | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Poster | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Patient Poster | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Patient Poster_v1_0_04JUL25_DE | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Physician Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Physician Referral Letter | 1.9 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Physician Referral Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Physician Referral Letter | 1.0 |
| Subject information and informed consent form (for publication) | L1_centre-specific contact list_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF Genetic_EN_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF Genetic_HU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF 16-17 years_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Adolescent Period 1_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Adolescent Period 2_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Adolescent_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Assent_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main adults_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main Period 1_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main Period 2_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_EN_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_HU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF OFR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF OFR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF OFR_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF OLE_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF OLE_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF OLE_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF OLE_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Optional Procedures for 16-17 years_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Optional Procedures Parent_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Optional Procedures_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Optional tests and Future Research_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Parent Period 1_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Parent Period 2_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Parent_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Parent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnancy Data Collection_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnancy Follow Up_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnancy Follow Up_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnancy Follow-up_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnancy FU_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnancy FU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnancy FU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnant Partner_EN_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnant Partner_HU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Adolescent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Adolescent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Adolescent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Assent 12-17 years_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GDPR Pregnancy follow-up | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GDPR Pregnancy follow-up | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GDPR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GDPR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main Assent 16-18 years_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main LAR of the Minor_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main Parent_BE-FR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main Parent_BE-NL_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_BE-FR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_BE-NL_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_OLE Period only_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_OLE Period_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_OLE_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_OLE_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_OLE_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_OLE_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Assent 16-18 years_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional biopsies_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional biopsies_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional future research | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional future research | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional genetic testing in future research | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional genetic testing in future research | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional genetic testing_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional genetic testing_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional intestinal ultrasound_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional_adults_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional_LAR of the Minor_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Parent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Parent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Parent_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Parent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Parent_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pediatric Assent_BE-FR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pediatric Assent_BE-NL_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PIS_Use of Personal Data_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy Follow up_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy follow-up | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy follow-up | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_Assent 16-18 years_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_BE-FR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_BE-NL_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_LAR of the Minor_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy FU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS Genetic_EN_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS Genetic_HU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_Sponsor statement on the use of ICF model_Redacted | N/A |
| Subject information and informed consent form (for publication) | L2_Other patient information_GP Letter_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other patient information_Participant reimbursement form_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Vendor DPN_redacted | N/A |
| Subject information and informed consent form (for publication) | L2_Patient Card_EN_public | 1.0 |
| Subject information and informed consent form (for publication) | L2_Patient Card_HU_public | 1.0 |
| Subject information and informed consent form (for publication) | L2_SIS and ICF_Other subject information material_Instructions_placeholder for publication | N/A |
| Synopsis of the protocol (for publication) | D1_lay-protocol-synopsis-nl-NL-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-bg-BG-2025-521037-86-00 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-cz-CZ-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-de-AT_2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-de-BE-2025-521037-86-00 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-en-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-es-ES-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-fr-BE-2025-521037-86-00 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-fr-FR-2025-521037-86-00 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-gr-GR-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-hu-HU-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-it-IT-2025-521037-86-00 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-lt-LT-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-nl-BE-2025-521037-86-00 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-no-NO-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-pl-PL-2025-521037-86-00 | 1 |
| Synopsis of the protocol (for publication) | d1-lay-protocol-synopsis-sk-SK-2025-521037-86 | 1 |
| Synopsis of the protocol (for publication) | d1-rdct-scientific-protocol-synopsis-de-AT-2025-521037-86 | 1 |
Application history
9 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-10-20 | Austria | Acceptable 2026-02-23
|
2026-02-24 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2026-03-10 | Austria | Acceptable 2026-02-23
|
2026-03-10 |
| 3 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2026-03-11 | Acceptable 2026-02-23
|
2026-03-11 | |
| 4 | SUBSTANTIAL MODIFICATION | SM-3 | 2026-03-23 | Acceptable | 2026-04-29 | |
| 5 | SUBSTANTIAL MODIFICATION | SM-4 | 2026-03-30 | Acceptable | 2026-05-12 | |
| 6 | SUBSTANTIAL MODIFICATION | SM-6 | 2026-03-30 | Acceptable | 2026-05-08 | |
| 7 | SUBSTANTIAL MODIFICATION | SM-5 | 2026-03-31 | Acceptable | 2026-04-07 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-2 | 2026-04-01 | Acceptable | 2026-05-08 | |
| 9 | SUBSTANTIAL MODIFICATION | SM-8 | 2026-04-24 | Acceptable | 2026-05-12 |